Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia

Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia

Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator of cancer-associated anorexia and may be therapeutically targeted to improve patient outcomes.

Bibliographic Details
Main Authors: Brennan Olson, Xinxia Zhu, Mason A. Norgard, Peter R. Levasseur, John T. Butler, Abigail Buenafe, Kevin G. Burfeind, Katherine A. Michaelis, Katherine R. Pelz, Heike Mendez, Jared Edwards, Stephanie M. Krasnow, Aaron J. Grossberg, Daniel L. Marks
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-22361-3

Internet

https://doi.org/10.1038/s41467-021-22361-3

Similar Items